GS
ASMB icon

Gilead Sciences’s Assembly Biosciences ASMB Stock Holding History

Gilead Sciences’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125M Hold
4,505,391
– – 5.9% 4
2025
Q4 		$153M Hold
4,505,391
– – 7.92% 4
2025
Q3 		$115M Buy
4,505,391
+2,295,920
+104% +$50.4M 6.44% 4
2025
Q2 		$40M Hold
2,209,471
– – 3.13% 4
2025
Q1 		$21.1M Hold
2,209,471
– – 1.79% 4
2024
Q4 		$34.9M Buy
+2,209,471
New +$35.6M 2.25% 4

Other funds holding ASMB

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gilead Sciences's ASMB Position: Q1 2026 in Review

Gilead Sciences held its Assembly Biosciences (ASMB) position steady in Q1 2026 at 4,505,391 shares worth $125M. The position accounts for 5.9% of the portfolio, ranked #4.

Gilead Sciences first reported a position in ASMB in Q4 2024 and has held it in 6 quarters since. The position peaked at $153M in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Gilead Sciences held 4,505,391 shares of Assembly Biosciences worth $125M as of Q1 2026.
  • Gilead Sciences left its Assembly Biosciences share count unchanged in Q1 2026.
  • Assembly Biosciences made up 5.9% of Gilead Sciences's portfolio in Q1 2026, its #4 holding.
  • Gilead Sciences first reported a position in Assembly Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Gilead Sciences's Assembly Biosciences position peaked at $153M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Gilead Sciences's 13F filing for Q1 2026, filed 8 May 2026.